Obicetrapib, a next-generation cholesteryl ester transfer protein (CETP) inhibitor, is emerging as a potent therapeutic option to address residual cardiovascular risk in patients not achieving optimal outcomes with existing lipid-lowering therapies, such as statins, ezetimibe and proprotein convertase subtilisin/kexin...
P. Thandi, Akshyaya Pradhan, R. Agarwala et al.· European Cardiology Review· 0 citations
Resistant hypertension (RH) is a high-risk phenotype associated with increased cardiovascular and renal morbidity despite multidrug therapy. Dysregulation of the renin–angiotensin–aldosterone system (RAAS), particularly excess aldosterone activity, plays a central role in the pathophysiology of RH. Although conventiona...
Akshyaya Pradhan, M. Bhandari, Abhishek Singh et al.· Life· 0 citations
BACKGROUND
Acute coronary syndrome (ACS) remains a leading cause of cardiovascular morbidity and mortality worldwide. High-throughput omics technologies offer opportunities for more comprehensive understanding of ACS pathophysiology.
METHODS
A systematic review was conducted in accordance with PRISMA 2020 guidelines....
Y. Sharma, Ankur Mittal, Kraticka Singhal et al.· Indian Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
